The use of delamanid in the treatment of multidrug-resistant tuberculosis interim policy guidance
Drug resistance is a major threat to global tuberculosis (TB) care and control. WHO estimates that around 480,000 new multidrug-resistant tuberculosis (MDR-TB) cases occured in 2013. Current treatment regimens for drug-resistant TB are complex, lengthy, toxic and expensive. Only about one half of MD...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Geneva, Switzerland
World Health Organization
2014, [2014]
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references